EP Patent

EP4008355A1 — Pharmaceutical nanoparticles showing improved mucosal transport

Assigned to Alcon Inc · Expires 2022-06-08 · 4y expired

What this patent protects

Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucuspenetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions…

USPTO Abstract

Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucuspenetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Drugs covered by this patent

Patent Metadata

Patent number
EP4008355A1
Jurisdiction
EP
Classification
Expires
2022-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.